EPS for Palatin Technologies, Inc. (PTN) Expected At $-0.04

August 24, 2017 - By Adrian Erickson

 EPS for Palatin Technologies, Inc. (PTN) Expected At $ 0.04
Investors sentiment decreased to 1.38 in Q4 2016. Its down 0.79, from 2.17 in 2016Q3. It turned negative, as 6 investors sold Palatin Technologies, Inc. shares while 7 reduced holdings. 9 funds opened positions while 9 raised stakes. 27.32 million shares or 111.47% more from 12.92 million shares in 2016Q3 were reported.
Geode Capital Mngmt Ltd Liability owns 674,147 shares or 0% of their US portfolio. Kcg holds 0% or 60,303 shares in its portfolio. Sphera Funds Mngmt accumulated 2.91M shares. Cetera Advsr Ltd Limited Liability Company accumulated 16,155 shares. Highlander Cap Ltd Com has 0.02% invested in Palatin Technologies, Inc. (NYSEMKT:PTN) for 50,000 shares. Financial Bank Of America De reported 0% of its portfolio in Palatin Technologies, Inc. (NYSEMKT:PTN). Jpmorgan Chase owns 2,300 shares for 0% of their portfolio. Wealthtrust Axiom Lc reported 28,035 shares. Raymond James Financial Advsrs Inc has invested 0% in Palatin Technologies, Inc. (NYSEMKT:PTN). Millennium Mngmt Ltd Liability Corp reported 0% of its portfolio in Palatin Technologies, Inc. (NYSEMKT:PTN). Qvt Financial L P holds 0.07% or 6.36M shares. 15,397 were reported by Blackrock Fund Advsr. Vanguard reported 0% of its portfolio in Palatin Technologies, Inc. (NYSEMKT:PTN). State Street holds 17,409 shares or 0% of its portfolio. Baker Bros Advisors Limited Partnership invested in 0.01% or 2.05M shares.

Analysts await Palatin Technologies, Inc. (NYSEMKT:PTN) to report earnings on September, 19. They expect $-0.04 EPS, up 55.56 % or $0.05 from last year’s $-0.09 per share. After $-0.02 actual EPS reported by Palatin Technologies, Inc. for the previous quarter, Wall Street now forecasts 100.00 % negative EPS growth. About 72,061 shares traded. Palatin Technologies, Inc. (NYSEMKT:PTN) has declined 19.98% since August 24, 2016 and is downtrending. It has underperformed by 36.68% the S&P500.

Palatin Technologies, Inc. is a biopharmaceutical company. The company has market cap of $60.46 million. The Firm is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. It currently has negative earnings. The Company’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

More notable recent Palatin Technologies, Inc. (NYSEMKT:PTN) news were published by: Prnewswire.com which released: “Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results …” on May 16, 2017, also Prnewswire.com with their article: “Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results …” published on February 09, 2017, Prnewswire.com published: “Palatin Technologies To Present At The 29th Annual ROTH Conference” on November 10, 2016. More interesting news about Palatin Technologies, Inc. (NYSEMKT:PTN) were released by: Reuters.com and their article: “Exclusive: Female Viagra contender Palatin Technologies explores potential …” published on November 02, 2016 as well as Seekingalpha.com‘s news article titled: “Palatin Technologies Has Great Upside Potential” with publication date: February 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.